JP2020535843A5 - - Google Patents

Download PDF

Info

Publication number
JP2020535843A5
JP2020535843A5 JP2020537814A JP2020537814A JP2020535843A5 JP 2020535843 A5 JP2020535843 A5 JP 2020535843A5 JP 2020537814 A JP2020537814 A JP 2020537814A JP 2020537814 A JP2020537814 A JP 2020537814A JP 2020535843 A5 JP2020535843 A5 JP 2020535843A5
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020537814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535843A (ja
JP7317023B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2018/051174 external-priority patent/WO2019056106A1/en
Publication of JP2020535843A publication Critical patent/JP2020535843A/ja
Publication of JP2020535843A5 publication Critical patent/JP2020535843A5/ja
Application granted granted Critical
Publication of JP7317023B2 publication Critical patent/JP7317023B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020537814A 2017-09-20 2018-09-20 新規抗hla-a2抗体、およびその使用 Active JP7317023B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762560841P 2017-09-20 2017-09-20
US62/560,841 2017-09-20
US201862691027P 2018-06-28 2018-06-28
US62/691,027 2018-06-28
PCT/CA2018/051174 WO2019056106A1 (en) 2017-09-20 2018-09-20 NOVEL ANTI-HLA-A2 ANTIBODIES AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2020535843A JP2020535843A (ja) 2020-12-10
JP2020535843A5 true JP2020535843A5 (https=) 2021-11-04
JP7317023B2 JP7317023B2 (ja) 2023-07-28

Family

ID=65810548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020537814A Active JP7317023B2 (ja) 2017-09-20 2018-09-20 新規抗hla-a2抗体、およびその使用

Country Status (12)

Country Link
US (2) US11814432B2 (https=)
EP (1) EP3684822A4 (https=)
JP (1) JP7317023B2 (https=)
KR (1) KR102740924B1 (https=)
CN (1) CN111448216B (https=)
AU (1) AU2018338423B2 (https=)
BR (1) BR112020005519A2 (https=)
CA (1) CA3076547A1 (https=)
IL (1) IL273401B2 (https=)
MX (1) MX2020003047A (https=)
SG (1) SG11202002532XA (https=)
WO (1) WO2019056106A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11827705B2 (en) 2017-03-28 2023-11-28 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
SG11202002520UA (en) 2017-09-19 2020-04-29 Univ British Columbia Anti-hla-a2 antibodies and methods of using the same
WO2021007396A2 (en) * 2019-07-09 2021-01-14 The Children's Mercy Hospital Engineered regulatory t cells
AU2020333659A1 (en) * 2019-08-16 2022-02-24 H. Lee Moffitt Cancer Center And Research Institute Inc. Anti-CD83 chimeric antigen receptor expressing t regulatory cells
CN111393533B (zh) * 2020-04-16 2021-05-11 成都仕康美生物科技有限公司 靶向HLA-A的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途
CN111440246B (zh) * 2020-04-16 2022-03-18 成都仕康美生物科技有限公司 靶向HLA-B的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途
CA3188867A1 (en) 2020-08-20 2022-02-24 Xueyin Wang Compositions and methods for treating ceacam positive cancers
WO2023019144A1 (en) * 2021-08-10 2023-02-16 The Regents Of The University Of California Hla-a2-specific regulatory t cells
EP4479143A1 (en) * 2022-02-18 2024-12-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
CN114316056A (zh) * 2022-03-02 2022-04-12 天津一瑞生物科技股份有限公司 一种鼠抗ndm型碳青霉烯酶杂交瘤细胞株,单克隆抗体及应用
AU2023229697A1 (en) * 2022-03-08 2024-09-19 Vaxcell-Bio Co., Ltd. Pd-l1-specific chimeric antigen receptor and immune cell comprising same
WO2026008994A1 (en) 2024-07-04 2026-01-08 Quell Therapeutics Limited Expression construct

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
ES2298745T3 (es) 2003-04-24 2008-05-16 Fondazione Centro San Raffaele Del Monte Tabor Promotores bidireccionales de sintesis y utilizacion de los mismos.
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Cdc45l胜肽與含此胜肽之疫苗
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
GB0919751D0 (en) * 2009-11-11 2009-12-30 King S College Hospital Nhs Fo Conjugate molecule
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2832540C (en) 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
JP2015180607A (ja) 2012-08-01 2015-10-15 国立大学法人 東京大学 移植片対宿主病などの造血幹細胞移植に伴う疾患を治療することのできる抗体およびその機能断片並びにこれらを含んでなる医薬組成物
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
CN103739667B (zh) * 2013-09-24 2017-08-25 上海宇研生物技术有限公司 卵巢癌特异的肿瘤抗原肽及其制备方法
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
US11827705B2 (en) 2017-03-28 2023-11-28 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
SG11202002520UA (en) 2017-09-19 2020-04-29 Univ British Columbia Anti-hla-a2 antibodies and methods of using the same

Similar Documents

Publication Publication Date Title
JP2020535843A5 (https=)
JP7150880B2 (ja) 抗-b7-h3抗体およびその用途
CN108026169B (zh) 抗人cd137的完全人抗体及其应用
JP2023539245A5 (https=)
WO2021063330A1 (zh) 靶向cd3的抗体、双特异性抗体及其用途
JP2019116474A5 (https=)
IL273401B2 (en) Novel antibodies against human leukocyte antigens type A2 and their uses
JP2019513370A5 (https=)
JP2017536341A5 (https=)
IL261666B1 (en) Binding proteins and methods of use thereof
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
TW201922784A (zh) 4﹘1bb抗體及其製備方法和應用
JP2018502050A5 (https=)
JP2018522888A5 (https=)
JP2022542559A5 (https=)
US20240101675A1 (en) Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
JP2019515648A5 (https=)
TW202221035A (zh) 抗ilt2抗體及其用途
TW202315889A (zh) 抗體
JP2016518333A5 (https=)
WO2023036326A1 (zh) 抗人cd3抗体及其应用
TW202246341A (zh) 針對NKp46的抗體及其應用
CN119161478A (zh) α5β1整合素结合剂及其用途
US20240409625A9 (en) Engineered dual binding antibodies and uses thereof